All sponsors

Kite, A Gilead Company $GILD

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING0
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%

Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +30.0 months). See all sponsors →

Open Kite, A Gilead Company on the live radar map → 📅 $GILD readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
iMMagine-1
NCT05396885
P2Active, not recruitingMultiple Myeloma1362026-12 (+30 mo)
JKART-1
NCT06253663
P2Active, not recruitingRelapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia252027-07 (+2 mo)
iMMagine-3
NCT06413498
P3Active, not recruitingMultiple Myeloma4522028-07
PALISADES-1
NCT04989803
P1/2Active, not recruitingRelapsed and/or Refractory B-cell Lymphoma2472030-02 (+49 mo)
ZUMA-22
NCT05371093
P3Active, not recruitingRelapsed/Refractory Follicular Lymphoma2312030-10 (+42 mo)
ZUMA-23
NCT05605899
P3Active, not recruitingHigh-risk Large B-cell Lymphoma (LBCL)3002031-03
KITE-753
NCT07479797
P3Active, not recruitingRelapsed or Refractory Large B-cell Lymphoma5502031-05
iMMagine-6
NCT07903506
P3Not yet recruitingNewly Diagnosed Multiple Myeloma7502039-03
iMMagine-4
NCT07887672
P3Not yet recruitingNewly Diagnosed Multiple Myeloma6002042-02